Addex Spin-Out Neurosterix Publishes Preclinical Data for Anxiety Treatment
ADXN sits 18% above its 52-week low of $6.51 on light trading volume (0.3× avg).
Summary
Addex Therapeutics announced the publication of preclinical data in Molecular Psychiatry, supporting the potential of mGlu7 Negative Allosteric Modulators (NAMs) from its spin-out, Neurosterix, to treat anxiety and fear-related disorders.
Key Events · Product Development and Regulatory · ADXN
-
Preclinical Data Publication
Addex announced the publication of preclinical data in Molecular Psychiatry for ADX71743, an mGlu7 Negative Allosteric Modulator (NAM).
-
Potential for Anxiety & Fear Disorders
The data supports the potential of mGlu7 NAMs to transform treatment for anxiety and fear-related disorders, including PTSD, by disrupting fear memory reconsolidation.
-
Neurosterix Asset Validation
ADX71743 and other mGlu7 NAMs are part of the portfolio of Neurosterix LLC, Addex's spin-out in which Addex holds a 20% equity interest, validating a key strategic investment.
Analysis · ADXN · Life Sciences
This filing highlights positive preclinical data for ADX71743, an mGlu7 NAM, demonstrating its potential to disrupt fear memory reconsolidation. The data, published in a peer-reviewed journal, provides scientific validation for a differentiated mechanism to treat anxiety and fear-related disorders like PTSD. While ADX71743 is part of the Neurosterix pipeline (in which Addex holds a 20% equity interest), this publication reinforces the scientific foundation of the spin-out's assets and Addex's strategic investment. This follows the recent announcement on January 7, 2026, of Neurosterix commencing a Phase 1 study for another mGlu7 NAM, NTX-253, further building momentum for the platform.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADXN was trading at $7.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $6.51 to $12.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.